Reporting owner · CIK 0001619834
Burke Steven Keith
Visual SEC Form 4 history across 2 companies, 12 transactions and 5 filings.
DIRSCYNEXIS INC
Open-market mix
0%buys
Open-market buy performance
90-day forward return on this insider's open-market purchases
Forward return is not available yet
We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for this insider's their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.
Disclosed ownership
How reported shareholdings evolved
Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.
1 observations · Sep 18, 2026 – Sep 18, 2026. Window ends at the latest available report, not today.
Selected observation · Sep 18, 20265,750 shares reported
Inspect transaction View exact observations and source transactions
| Transaction date | Shares held after | Filed | Source |
|---|---|---|---|
| Sep 18, 2026 | 5,750 | Sep 22, 2026 | View transaction |
Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.
Monthly open-market activity
Reported purchase and sale transaction counts
Buys Sells
Net value flow
Buys minus sells
Jan 25
$0
Feb 25
−$106.1K
Mar 25
−$13.1K
Jan 26
$0
Feb 26
−$94K
Sep 26
$0
Transaction texture
Ownership and ticket size
Average P/S size$35.5K
Median P/S size$32.6K
Direct12
Indirect0
Sep 18, 2026grant
Filing-only signals
Deterministic matches in this insider's history
Latest Form 4 facts
Quick context from source filings
Latest transaction
sale at Akebia Therapeutics, Inc. on Feb 02, 2026 valued at $28,774.
Review SEC filingLatest buy
No open-market insider purchase is available.
Associated companies
Visual map of known reporting history
Latest insider transactions
Form 4 filings from available history. Click any column to sort; click it again to flip the order.
| ID | Ticker | Insider | Role | Type | Shares | Value | Code | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|
| #227408 | SCYX | Burke Steven Keith | DIR | grant | 5.75k | $0 | A | 09/22 | 09/18 |
| #227407 | SCYX | Burke Steven Keith | DIR | grant | 5.75k | $0 | A | 09/22 | 09/18 |
| #43604 | AKBA | Burke Steven Keith | SVPCMO | sale10b5-1 | 20.7k | -$2.87M | S | 02/04 | 02/02 |
| #43603 | AKBA | Burke Steven Keith | SVPCMO | sale10b5-1 | 25.3k | -$3.52M | S | 02/04 | 02/02 |
| #43602 | AKBA | Burke Steven Keith | SVPCMO | sale10b5-1 | 21.5k | -$2.99M | S | 02/04 | 02/02 |
| #40000 | AKBA | Burke Steven Keith | SVPCMO | grant | 320k | $0 | A | 02/03 | 01/30 |
| #39999 | AKBA | Burke Steven Keith | SVPCMO | grant | 204k | $0 | A | 02/03 | 01/30 |
| #185404 | AKBA | Burke Steven Keith | SVPCMO | sale10b5-1 | 7.14k | -$1.30M | S | 03/04/2025 | 03/03/2025 |
| #118314 | AKBA | Burke Steven Keith | SVPCMO | grant10b5-1 | 292k | $0 | A | 02/04/2025 | 01/31/2025 |
| #118313 | AKBA | Burke Steven Keith | SVPCMO | sale10b5-1 | 27.2k | -$5.71M | S | 02/04/2025 | 02/03/2025 |
Burke Steven Keith Insider Activity FAQ
SEC Form 4 context
Who is Burke Steven Keith?
Burke Steven Keith is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001619834.
Which companies has Burke Steven Keith reported transactions for?
SCYNEXIS INC, Akebia Therapeutics, Inc.
When was Burke Steven Keith's latest insider buy?
No open-market insider purchase is available for this period.
When was Burke Steven Keith's latest insider sale?
sale at Akebia Therapeutics, Inc. on Feb 02, 2026 valued at $28,774.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.